Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease
| Autor: | Giuseppe Macrì, Tommaso Mello, Maria Rosa Biagini, Tommaso Innocenti, L. Parisio, Jenny Roselli, Pasquale Apolito, Stefano Milani, E.N. Lynch, Mirko Tarocchi, Andrea Galli, Monica Milla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
History medicine.medical_specialty Polymers and Plastics Mucocutaneous zone Case Report Crohn's Disease Disease RC799-869 medicine.disease_cause Industrial and Manufacturing Engineering Virus 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine 0502 economics and business Adalimumab medicine Business and International Management skin and connective tissue diseases Crohn's disease business.industry Mortality rate 05 social sciences Diseases of the digestive system. Gastroenterology medicine.disease Dermatology humanities stomatognathic diseases Herpes simplex virus 050211 marketing business Adverse drug reaction medicine.drug |
| Zdroj: | Case Reports in Gastrointestinal Medicine, Vol 2020 (2020) Case Reports in Gastrointestinal Medicine |
| ISSN: | 2090-6536 2090-6528 |
| Popis: | Stevens–Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn’s disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNFα therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text